Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894635 | 0.89 | HTT (0.47) | LMNAHTTSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL893657 | 0.84 | CAMK1D (0.44) | LMNAHTTSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL10169191 | 0.78 | MAPK8 (0.54) | SMN1; SMN2KMT2AMAPTNPC1 | |
| SCHEMBL10169304 | 0.70 | SYK (0.52) | SMN1; SMN2MAPTNPC1 | |
| SCHEMBL6141196 | 0.69 | MAPT (0.53) | LMNASMN1; SMN2ALDH1A1MAPK1KMT2A | |
| SCHEMBL8171612 | 0.68 | DHODH (0.57) | LMNAHTTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL894820 | 0.68 | NR1H3 (0.56) | LMNAHTTSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL2397595 | 0.67 | GAA (0.56) | LMNAHTTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL846982 | 0.67 | MAPT (0.44) | LMNASMN1; SMN2ALDH1A1MAPK1KMT2A | |
| SCHEMBL10169201 | 0.66 | SYK (0.51) | HTTSMN1; SMN2ALDH1A1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | LMNA 3170/4885HTT 3854/4885SMN1; SMN2 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.